StreetAlpha.app
Home › Stocks › ARWR

Arrowhead Pharmaceuticals, Inc. (ARWR)

Healthcare
$41.37
▼ −5.22%
LAST CLOSE · NOV 20

Arrowhead Pharmaceuticals develops RNA interference medicines that silence disease genes, mainly for metabolic and liver conditions. It last closed at $41.37 on Nov 20, down 5.22% on the day. The next earnings report for ARWR is expected around Thu, Feb 4, 2027, after the close. For the quarter ended Sep 2026, ARWR reported EPS of -$3.01 on revenue of $37.8M, with revenue down 85.3% from a year ago. Over its last 8 reports the stock moved an average of 6.4% the session after earnings. Over the last 12 months ARWR insiders bought $0 of stock on the open market and sold $37.3M, according to SEC Form 4 filings.

AI Auto Pilots
Is ARWR in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ARWR.

Key Stats

Last 12 months
Results
Revenue
$450.8M
−45.6% vs a year ago
Net income
−$724.2M
−160.6% margin
EPS (diluted)
−$5.11
Free cash flow
−$283.9M
−63.0% margin
Valuation
Market cap
$5.8B
141.4M shares
P/E
–
No P/E while losing money
Price to sales
13.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$62.7M
At Sep 30
Shareholder equity
$50.3M
Shares outstanding
141.4M
At Nov 5
Fiscal year endsSeptember
ExchangeNasdaq
Financials history
FY2022: $243.2M$243.2MFY2022FY2023: $240.7M$240.7MFY2023FY2024: $3.6M$3.6MFY2024FY2025: $829.4M$829.4MFY2025FY2026: $450.8M$450.8MFY2026

From ARWR's SEC filings, latest 10-K for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Feb 4
Estimated date · After the close
Reported EPS
-$3.01
Quarter ended Sep 2026
Year ago EPS
-$0.18
Same quarter last year
Revenue
$37.8M
−85.3% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.39Dec '24Mar 2025: $2.75Mar '25Jun 2025: -$1.26Jun '25Sep 2025: -$0.18Sep '25Dec 2025: $0.22Dec '25Mar 2026: -$0.93Mar '26Jun 2026: -$1.36Jun '26Sep 2026: -$3.01Sep '26Latest -$3.01
Revenue by quarter
Dec 2024: $2.5MDec '24Mar 2025: $542.7MMar '25Jun 2025: $27.8MJun '25Sep 2025: $256.5MSep '25Dec 2025: $264.0MDec '25Mar 2026: $73.7MMar '26Jun 2026: $75.3MJun '26Sep 2026: $37.8MSep '26Latest $37.8M
How ARWR moved after its last 8 reports
Average move the session after a report ±6.4%
Nov 12, 2026After the close+1.3%
Aug 4, 2026After the close−3.0%
May 7, 2026After the close−6.8%
Feb 5, 2026After the close−0.2%
Nov 25, 2025After the close+23.3%
Aug 7, 2025After the close+2.2%
May 12, 2025After the close+9.4%
Feb 10, 2025After the close−5.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ARWRStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ARWR
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ARWR

Technical Analysis

ARWR · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 27% below its 20 day and 43% below its 50 day average. It is 70% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 21), oversold. The nearest support is the Pivot S1 at $40.09, and the nearest resistance the Pivot at $42.45.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 7.2%/day
Key levels
$95.4952 week high+130.8%
$71.74100 day average+73.4%
$70.43200 day average+70.2%
$60.46Swing high (Oct 21)+46.1%
$59.2450 day average+43.2%
$52.6420 day average+27.2%
$43.72Pivot R1+5.7%
$42.45Pivot+2.6%
$41.37Last close
$40.09Pivot S1−3.1%
$37.0652 week low−10.4%
Indicators
RSI (14)20.87Oversold below 30Oversold
MACD-5.30Below its signal lineBearish
Stochastic4.7Near the bottom of its rangeOversold
ADX (14)43.8Strong downtrend
Williams %R-99.0Oversold below −80, overbought above −20Oversold
CCI (20)-101.8Oversold below −100, overbought above 100Oversold
Rate of change−28.9%Change over 10 sessionsBearish
ATR (14)$2.96Typical daily range, 7.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ARWR

What happened before

See how ARWR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ARWR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ARWR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ARWRHow many large options trades hit ARWR, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

ARWR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●242 buying vs 249 selling
  • ▼Held by funds -1.3 pts
  • ▼Funds holding -17
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding488505−3.4%
In funds' top 10990.0%
Held by funds83.5%84.7%−1.3 pts
New / increased67 / 175124 / 153−12.6%
Reduced / sold out169 / 80157 / 58+15.8%
Put/call ratio0.240.35−29.6%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ARWR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ARWR Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$37.3M19 sales · 10 insiders
45% of the selling was under pre-arranged trading plans.
2025-12 sold $26.6M2026-01 sold $6.5M2026-03 sold $642K2026-04 sold $1.7M2026-05 sold $228K2026-08 sold $1.2MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 18Adeoye Y OlukotunDirectorSale2,000$86.96$174K
Aug 18Michael S PerryDirectorSale11,600$87.30$1.0M
May 12Hongbo LuDirectorSale plan2,970$76.88$228K
Apr 23James C HamiltonChief Medical OfficerSale plan10,000$75.00$750K
Apr 22Daniel Joseph ApelCFOSale plan13,095$71.35$934K
Mar 5James C HamiltonChief Medical OfficerSale plan10,000$64.19$642K
Every insider buy and sale for ARWR over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ARWR insider trades →

From SEC Form 4 filings by ARWR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARWR is in one of them and how their past ARWR trades turned out.

ARWR in the AI portfolios
Loading…

ARWR News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ARWR in an article yet. Here's the latest on the wider market.

ARWR in the news

ARWR Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Feb 24
Who traded ARWR · since 2023
Latest 1 filing
$1K – $15KTraded Jan 31, 2023Filed Feb 24, 2023
PersonTypeAmountTradedFiledDelay
Dan GoldmanD · NYSell$1K – $15KJan 31, 2023Feb 24, 202324 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is a biopharmaceutical company based in Pasadena, California. It develops medicines that use RNA interference to switch off genes that drive disease, aiming at conditions that traditional drugs have struggled to treat. Its approved product, REDEMPLO, treats adults with familial chylomicronemia syndrome, a rare genetic disorder that raises triglyceride levels. The company's pipeline targets lipid and liver diseases, and it licenses its technology to other drugmakers.

Headquarters
Pasadena, CA
Founded
1989